IDL Biotech Q1: First comment
Research Note
2019-04-18
09:36
IDL reports lower sales, but a higher EBIT than expected. Key takeaways are the return to growth in the Indonesian market and progression with clinical trials.
LS
Ludvig Svensson
Disclosures and disclaimers